Kevin McGovern Joins Reven's Board of Directors. Reven announces Kevin McGovern as the newest addition to its Board of Directors. Kevin McGovern Press Release
About Tanner ThomasThis author has not yet filled in any details.
So far Tanner Thomas has created 77 blog entries.
Reven Hires Dr. James Carlson. Dr. James Carlson hired as Reven's Executive Vice President of Development Dr. James Carlson Press Release here: Reven Press Release - 011719
On January 15, 2019 Reven completed their single-ascending-dose (SAD)/ multiple-ascending-dose (MAD) Phase 1 Clinical Trial in the United States. Reven is now in the planning stage of their Phase 2 Clinical Trial that will be conducted in the United States in Q2 of 2019.
MAD Cohort 3 completed dosing on January 15, 2019.
Reven Hires Susan Moore. Susan Moore hired as Reven's Senior Director of Regulatory and Clinical Affairs.
MAD Cohort 3 begins seven-day dosing period.
Reven Hires James Carlson. James Carlson hired as Reven's Executive Vice President of Development.
Reven Hires Natalie Pizzimenti. Natalie Pizzimenti hired as Reven's Clinical Research Scientist.
MAD Cohort 2 completed dosing on December 18, 2018.
MAD Cohort 2 begins seven-day dosing period.